Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madrigal PharmaceuticalsMDGL -0.37%31 Net Cash per Share is $5.10 as of Jun. 2026, which is 31% below its 10-year median of 7.37. GuruFocus rates MDGL with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 757 Biotechnology companies, Madrigal Pharmaceuticals ranks worse than 97.23% on this metric.
Madrigal Pharmaceuticals (NAS:MDGL) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Madrigal Pharmaceuticals Net Cash per Share Related Terms
Madrigal Pharmaceuticals Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDGL vs AXSM, ARWR, BMRN: Net Cash per Share Comparison
For the Biotechnology subindustry, Madrigal Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's Price-to-Net-Cash falls into.
Madrigal Pharmaceuticals Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Madrigal Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals (MDGL) has a Net Cash per Share of $5.10 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Madrigal Pharmaceuticals and its competitors. This is 31% below median its historical median of 7.37. Over the past decade, Madrigal Pharmaceuticals' Net Cash per Share has ranged from 2.69 to 209.65. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #736 out of 757 companies in the Biotechnology industry, placing it in the top 97.2%.
Is Madrigal Pharmaceuticals' Net Cash per Share too high?
Madrigal Pharmaceuticals' current Net Cash per Share of $5.10 is 31% below median its 10-year median of 7.37. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 209.65. The Biotechnology industry median Net Cash per Share is 5.17. Madrigal Pharmaceuticals' value of $5.10 is 1.4% below this industry median. Based on the distribution chart, Madrigal Pharmaceuticals ranks #736 out of 757 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Madrigal Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Net Cash per Share compare to AXSM and ARWR?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #736 out of 757 companies for Net Cash per Share. This places Madrigal Pharmaceuticals in the lower half of its industry. The industry median Net Cash per Share is 5.17. Madrigal Pharmaceuticals' value of $5.10 is 1.4% below this benchmark. Historically, Madrigal Pharmaceuticals' own Net Cash per Share has ranged from 2.69 to 209.65 over the past decade. While the company's 10-year median is 7.37 vs. the industry median of 5.17, Madrigal Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.17, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madrigal Pharmaceuticals's current Net Cash per Share of $5.10 is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Madrigal Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madrigal Pharmaceuticals's current Net Cash per Share is $5.10, which is 31% below median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MDGL) has a current Net Cash per Share of $5.10. The current Net Cash per Share is $5.10, which is 31% below median its 10-year median of 7.37 and 1.4% below the Biotechnology industry median of 5.17. Madrigal Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MDGL), the current Net Cash per Share is $5.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
31GF Score
Get the complete analysis for MDGL
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDGL has been successfully added to your 
